Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
November 13, 2022 18:15 ET
|
Ascendis Pharma
- Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment - The primary endpoint,...
Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022
November 11, 2022 12:10 ET
|
Ascendis Pharma
- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy - With a...
Ascendis Pharma Reports Third Quarter 2022 Financial Results
November 02, 2022 16:01 ET
|
Ascendis Pharma
- SKYTROFA® U.S. revenue more than doubled quarter-to-quarter again, reaching €12.3 million in the third quarter - FDA accepted for Priority Review TransCon™ PTH NDA in adult patients with...
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
October 31, 2022 08:00 ET
|
Ascendis Pharma
- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN, Denmark, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today...
Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2
October 26, 2022 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2,...
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors
October 03, 2022 08:00 ET
|
Ascendis Pharma
- TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab - Abstract for dose-escalation topline...
New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022
September 12, 2022 08:00 ET
|
Ascendis Pharma
- Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normalization of serum calcium and 93% achieving independence from conventional therapy - Participants...
Ascendis Pharma A/S Announces Upcoming Investor Presentations in September
September 01, 2022 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in...
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
August 31, 2022 08:27 ET
|
Ascendis Pharma
• TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated...
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
August 10, 2022 16:01 ET
|
Ascendis Pharma
— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 — SKYTROFA revenue continued...